Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Blood

Volumn 109, Issue 2, 2007, Pages 405-411

  Kay, Neil E ^a   Geyer, Susan M ^a   Call, Timothy G ^a   Shanafelt, Tait D ^a   Zent, Clive S ^a   Jelinek, Diane F ^a   Tschumper, Renee ^a   Bone, Nancy D ^a   Dewald, Gordon W ^a   Lin, Thomas S ^b   Heerema, Nyla A ^b   Smith, Lisa ^b   Grever, Michael R ^b   Byrd, John C ^b  

^a MAYO CLINIC   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; PENTOSTATIN; PROTEIN KINASE ZAP 70; RITUXIMAB;

ADULT; AGED; ARTICLE; ATAXIA; AUTOIMMUNE DISEASE; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RISK; CHROMOSOME DISORDER; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEAVY CHAIN; HUMAN; HYPERURICEMIA; HYPOTENSION; HYPOXIA; INFARCTION; INFECTION; ISCHEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MYALGIA; NAUSEA; NEURALGIA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; PRURITUS; RASH; SINUS BRADYCARDIA; TREATMENT RESPONSE; VOMITING;

EID: 33846258434     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-033274     Document Type: Article

References (35)

1. Han T, Ezdinli EZ, Shimaoka K, Desai DV. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer. 1973;31:502-508.
2. Hansen MM, Andersen E, Birgens H. CHOP versus chlorambucil + prednisolone in chronic lymphocytic leukemia. Leuk Lymphoma. 1991;5:97-100.
3. Raphael B, Andersen JW, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol. 1991;9:770-776.
4. Keller JW, Knospe WH, Raney M, et al. Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A Southeastern Cancer Study Group Trial. Cancer. 1986;58:1185-1192.
5. Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol. 1990;17:49-62.
6. Keating MJ, Kantarjian H, O'Brien S, et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol. 1991;9:44-49.
7. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
8. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43:1755-1762.
9. Schiavone EM, De Simone M, Palmieri S, et al. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia. Eur J Haematol. 2003;71:23-28.
10. Schmitt B, Wendtner CM, Bergmann M, et al. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clinl Lymphoma. 2002;3:26-35.
11. Flinn I, Grever M, Neuberg D, et al. Fludarabine and cyclophosphamide produces a significantly higher response rate and more durable remissions than fludarabine in patients with previously untreated CLL [abstract]. Blood. 2004;104:139a. Abstract 475.
12. Weiss MA, Glenn M, Maslak P, et al. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia. 2000;14:1577-1582.
13. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885-891.
14. Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003;21:1278-1284.
15. Oken MM, Lee S, Kay NE, Knospe W, Cassileth PA. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma. 2004;45:79-84.
16. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006;24:1575-1581.
17. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
18. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078.
19. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
20. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153-2164.
21. National Cancer Institute: Common Toxicity Criteria. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute; 1988.
22. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988;29:152-163.
23. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001;115:854-861.
24. Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003;121:287-295.
25. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
26. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
27. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
28. Catovsky D, Richards S, Matutes E et al. Response to therapy and survival in CLL is influenced by genetic markers. Preliminary analysis from the LRF CLL4 trial [abstract]. Blood. 2004;104:8a. Abstract 13.
29. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL [review]. Blood. 2004;103:1202-1210.
30. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24:437-443.
31. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.
32. Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica. 2005;90:1435-1436.
33. Stilgenbauer S, Kröber, Busch R, et al. 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG [abstract]. Blood. 2005;106:212a. Abstract 715.
34. Grever MR, Lucas DM, Dewald DW, et al. Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) is adversely impacted by high risk genetic features: results from ECOG 2997 [abstract]. Blood. 2004;104:950a-951a. Abstract 3487.
35. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.